Groprinosin 500mg 50 pills

Groprinosin - immunostimulating drug with antiviral effect. It is a complex containing inosine and 4-acetamidobenzoic acid salt with N, N-dimethylamino-2-propanol in a molar ratio of 1: 3.

The effectiveness of the complex is determined by the presence of inosine, the second component increases its availability for lymphocytes. Groprinosin blocks the multiplication of viral particles by damaging the genetic apparatus, stimulates macrophage activity, proliferation of lymphocytes and the formation of cytokines.

Reduces the clinical manifestations of viral diseases, accelerates convalescence, increases the resistance of the body.

When Gropronosin is prescribed as an auxiliary drug for infection of the mucous membranes and skin caused by the Herpes simplex virus, faster healing of the affected surface occurs than with conventional treatment. More rarely new vesicles, swelling, erosion and relapse of the disease. With the timely use of the drug, the incidence of viral infections decreases, the duration and severity of the disease decreases.

Pharmacokinetics

Suction

After ingestion, the drug quickly and almost completely (> 90%) is absorbed and has good bioavailability. When administered orally at a dose of 1500 mg Cmax, inosine pranobex is achieved after 1 hour and is 600 μg / ml. Not detected in the blood after 2 hours after ingestion.

Distribution and Metabolism

Inosine pranobex consists of inosine and p-acetamidobenzoic acid salt with N, N-dimethylamino-2-propanol. Each of the components of inosine pranobex is rapidly metabolized. Virtually 100% of metabolites are found in the urine in the range of 8 to 24 hours from the time of admission. Inosine is metabolized by a cycle typical of purine nucleotides, with the formation of uric acid, the concentration of which in the blood serum can increase. As a result, it is possible to form crystals of uric acid in the urinary tract. The increase in the concentration of uric acid is non-linear and can vary by ± 10% within 1-3 hours after ingestion. As a result of the metabolism of p-acetamidobenzoic acid, o-acylglucuronide is formed; N, N-dimethylamino-2-propanol is metabolized to the N-oxide. AUC of p-acetamidobenzoic acid> 88%, AUC of N, N-dimethylamino-2-propanol> 77%. Cumulation drug in the body is not found.

Excretion

Inosine and its metabolites are excreted in the urine. When the equilibrium concentration is reached with a daily dose of 4 g, the daily urinary excretion of p-acetamidobenzoic acid and its metabolite is approximately 85% of the dose taken; T1 / 2 - 50 min. T1 / 2 N, N-dimethylamino-2-propanol, 3-5 hours.

Complete elimination of inosine pranobeksa and its metabolites from the body occurs within 48 hours.

Indications:

• immunodeficiency states caused by viral infections in patients with normal and weakened immune system, incl. diseases caused by Herpes simplex virus types 1 and 2 (including genital herpes and herpes of other localization);
• subacute sclerosing panencephalitis.

Contraindications:

• gout;
• urolithiasis disease;
• arrhythmia;
• chronic renal failure;
• children under 3 years old (body weight up to 15-20 kg);
• pregnancy;
• lactation period (breastfeeding);
• hypersensitivity to the components of the drug.

With caution should prescribe a drug with inhibitors of xanthine oxidase, diuretics, zidovudine, with acute renal failure.

Suggested Use:

The drug is taken orally after meals, at regular intervals (8 or 6 hours) 3-4 times / day.

Tablets are taken with a small amount of water.

Adults prescribe from 6 to 8 tablets / day in 3-4 reception.

Children aged 3 to 12 years are prescribed a dose of 50 mg / kg / day, divided into 3-4 doses.

In both adults and children, in severe infectious diseases, the dose can be individually increased to 100 mg / kg of body weight / day, divided into 4-6 receptions. The maximum daily dose in adults is 3-4 g, the maximum daily dose in children is 50 mg / kg.

In acute diseases, treatment usually lasts from 5 to 14 days. After the disappearance of symptoms, treatment should be continued for 1-2 days or more, depending on the indications.

In chronic relapsing diseases, treatment in adults and children is conducted with courses lasting 5-10 days at intervals of 8 days.

The duration of maintenance treatment can be up to 30 days, with the dose can be reduced to 0.5-1 g / day.

Treatment of infections caused by the herpes virus in adults and children: should take several courses, lasting 5-10 days before the disappearance of symptoms. To reduce the number of relapses it is recommended to carry out maintenance treatment for 1 tab. 2 times / day for 30 days.

There is no need for dose adjustment in elderly patients, the drug is used in the same way as in middle-aged patients. In elderly patients, the concentration of uric acid in serum and urine increases more often than in middle-aged patients.

The drug is used in children older than 3 years.

Against the background of treatment with Groprinosin, patients with hepatic insufficiency should be monitored every 2 weeks for uric acid in the serum and urine. It is recommended to monitor the activity of hepatic enzymes every 4 weeks with prolonged courses of treatment with the drug.

Special instructions:

Groprinosin, like other antiviral agents, is most effective in acute viral infections if treatment is started at an early stage of the disease (better from the first day).

Since inosine is excreted from the body in the form of uric acid, with prolonged use it is recommended to periodically monitor the concentration of uric acid in serum and urine. Patients with a significantly increased concentration of uric acid in the body can simultaneously take drugs that lower its concentration.

It is necessary to monitor the concentration of uric acid in the blood serum when taking Groprinosin simultaneously with drugs that increase the concentration of uric acid, or drugs that disrupt kidney function.

Grogrinosin should be used with caution in patients with acute liver failure, because the drug is metabolized in the liver.

Impact on the ability to drive vehicles and manage mechanisms

The effect of Groprinosin on the psychomotor functions of the body and the ability to control vehicles and moving mechanisms has not been investigated. When using the drug should take into account the possibility of dizziness and drowsiness.

Application for violations of liver function

Patients with acute hepatic impairment require a reduction in the dose of the drug. the process of metabolism of inosine pranobeks occurs in the liver.

Application for violations of kidney function

The drug is contraindicated in urolithiasis.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!